#Czech Republic #Ostrava #Stimvia #URIS® Therapy #OAB Treatment

Stimvia Enhances Scientific Advisory Board and Commercial Leadership

Stimvia, a Czech Republic-based medical technology firm, is making significant strides in its mission to provide non-invasive neuromodulation therapies for overactive bladder (OAB). The company has recently announced the expansion of its Scientific Advisory Board, alongside an enhancement of its international commercial leadership team. This strategic move marks a pivotal moment in growing the global market for its flagship therapy, URIS®.

Strengthening Clinical Expertise

To further solidify its clinical and scientific standing, Stimvia has brought on board several experts from the fields of urology and medical technology. Their presence aims to drive market development and boost the international adoption of URIS®. The newly appointed Scientific Advisory Board includes:

• - Dr. David R. Staskin: A renowned urologist from Boston, USA, who has extensive expertise in lower urinary tract disorders and a background in medical device development.
• - Prof. Alan J. Wein, MD, PhD (Hon), FACS: Former Chief of Urology at the University of Pennsylvania and a prominent contributor to international guidelines regarding OAB treatments.
• - Prof. Christopher R. Chapple: A leading international figure in functional and reconstructive urology, based in the UK.
• - Prof. Bertil Blok: Recognized for his expertise in neuro-urology and functional urology, affiliated with institutions in the Netherlands.

With such leading figures on its board, Stimvia aims to enhance collaboration with top clinicians, generate robust evidence for its therapies, and reinforce trust among healthcare professionals and investors alike.

Building a Commercial Engine

On the commercial side, Stimvia has made strategic hires to accelerate its growth. Dr. David da Silva has been appointed to oversee global distribution and market development. With over ten years of experience in leadership roles at various MedTech companies, including Medtronic and Stryker, he is well-prepared to focus on scalable channel partnerships and entry strategies across Europe, Latin America, and other key markets.

Additionally, Alim Topdag, MSc has joined as Director of Sales and Business Development for markets outside the United States. His role will focus on expanding sales across priority territories through collaborations with distributors and direct commercial models. He will also work on clinical and technical implementation, fostering the adoption of URIS® as a therapy option.

By merging top-tier clinical guidance with dynamic commercial leadership, Stimvia is laying a robust foundation for the international adoption of URIS®, positioning the company for the next phase of growth within the global urology market. The commitments made by both the scientific advisory and commercial teams are set to place Stimvia at the forefront of OAB treatment advancements.

As the company moves forward, the enhanced credibility and commercial strategies are expected to propel Stimvia’s URIS® therapy towards becoming a leading solution for patients suffering from overactive bladder, ultimately aiming to improve their quality of life.

This strategic overhaul positions Stimvia not just as a participant, but as a leader in revolutionary treatments for urological disorders, reflecting its commitment to innovation and patient-centered care.